Tovorafenib

Ojemda

25 MG / ML Powder For SuspensionCanadaAuthorised

In other countries

The same active substances on other registers, the same brand first.

Documents

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Tovorafenib

Ojemda

25 MG / ML Powder For SuspensionCanadaAuthorised

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Documents

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

The official texts, at the regulator.

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Tovorafenib
Strength: 25 MG / ML
Dosage form: Powder For Suspension
Route: Oral
Register: Canada (Health Canada)
Status: Authorised
Status in the register: Approved
Registration: DIN 02569876
Marketing authorisation holder: Ipsen Biopharmaceuticals Canada INC
ATC code: L01EC04
Group: Antineoplastic and immunomodulating agents
Supply: PRESCRIPTION